Singulex’s Clarity C. diff toxin A/B assay, a rapid C. diff toxin test, has made its commercial debut, the company announced. “The Clarity toxin A/B assay offers a new approach to testing for ...

Singulex anticipates FDA registration for the Singulex Clarity C. diff toxin A/B assay by the end of 2018. Niamh Nolan is Director of Clinical Research and Medical Affairs at Singulex ...

Researchers screened patients for C. diff using real-time PCR, a toxin enzyme-linked immunosorbent assay and a toxigenic culture. C. diff was detected in 18 percent of the participants using real ...

Scientists make breakthrough in C. diff vaccine development Automation in action: Inside Priority Health’s operational overhaul Recommended Live Webinar on Jul 15, 2025 1:00 PM - 2:00 PM CDT ...

CHICAGO, Ill. (WPVI) -- A new drug to treat C. Difficile, also known as C. Diff, is getting C. diff is a common bacterial infection of the gut, and it can be deadly. In two Phase 3 clinical trials ...

C. diff is a type of bacterium that can cause gastrointestinal symptoms, such as diarrhea and stomach cramps. Discover how this bacterium is transmitted and its treatment options.

The largest study of its kind has shown the most effective test for the diagnosis of Clostridium difficile (C-Diff), a bacterial infection which causes 15,000-20,000 deaths a year in hospitals in ...

The study compared the main different ways of diagnosing C-Diff, including the two 'gold-standard' methods: a cytotoxin assay, which looks for the presence of C-Diff toxin in faecal samples; and ...

Thanks to multi-disciplinary risk assessment process, Rhode Island Hospital saw hospital-onset Clostridium difficile (C.diff) drop 70 percent while deaths associated with the hospital-acquired ...

A newly published paper in PNAS details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff -- a virulent health care-associated ...

No C. diff vaccine is currently in widespread use. Some toxin-based vaccines are currently in clinical trials, but the Exeter research offers a promising new approach.

Researchers conducted a study of all hospitalized patients with a positive fecal CDI toxin assay result in three university-affiliated hospitals from July 2006-Oct. 2006. Eight CDI severity scores ...